Results 131 to 140 of about 157,199 (404)

Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic‐Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney Transplantation

Clinical Pharmacology &Therapeutics, EarlyView.
Alemtuzumab is a T cell‐depleting monoclonal antibody that is used for the prevention of kidney transplant rejection. The duration of lymphodepletion after the current standard induction therapy dose is likely longer than necessary, resulting in prolonged T cell lymphopenia with the associated risk of infections. Here, the interplay between alemtuzumab
Lukas K. van Vugt, Tom C. Zwart, Suzanne Bezstarosti, Sebastiaan Heidt, Marlies E. J. Reinders, Dennis A. Hesselink, Aiko P. J. de Vries, Brenda C. M. de Winter, Dirk Jan A. R. Moes   +8 more
wiley   +1 more source

Postoperative association between impaired renal function and vascular dysfunction in liver transplant recipients

, 2022
Liver Transplantation, EarlyView.
Domenico A. Chavez, Marie‐Claire Evans, Natalie J. Bohmke, Hiba Kamal, Loan Quynh Tran, Chandra Bhati, Susan Wolver, Mohammad S. Siddiqui, Danielle L. Kirkman   +8 more
wiley   +1 more source

Seasonal relapsing minimal change disease: a novel strategy for avoiding long-term immunosuppression. [PDF]

, 2012
BACKGROUND: We describe the case of a young woman with seasonal allergic rhinitis who presented with signs of a lower respiratory tract infection, acute renal impairment and the nephrotic syndrome, demonstrated on biopsy to be due to minimal change ...
Cook, HT, Lawrence, C, Lightstone, L
core   +2 more sources

Treatment of Acute Tacrolimus Toxicity with Phenytoin in Solid Organ Transplant Recipients

Case Reports in Transplantation, 2013
The pharmacokinetics of tacrolimus are influenced by many factors, including genetic variability, acute infections, liver dysfunction, and interacting medications, which can result in elevated concentrations.
Arin S. Jantz, Samir J. Patel, Wadi N. Suki, Richard J. Knight, Arvind Bhimaraj, A. Osama Gaber   +5 more
doaj   +1 more source

Blood Level of Tacrolimus in Patients with Severe Allergic Conjunctivitis Treated by 0.1% Tacrolimus Ophthalmic Suspension

Allergology International, 2012
Background: To estimate the efficacy and safety of 0.1% tacrolimus ophthalmic suspension based on the blood level of tacrolimus in patients with severe allergic conjunctivitis.
Nobuyuki Ebihara, Yuichi Ohashi, Hiroshi Fujishima, Atsuki Fukushima, Yayoi Nakagawa, Kenichi Namba, Shigeki Okamoto, Jun Shoji, Etsuko Takamura, Eiichi Uchio, Dai Miyazaki   +10 more
doaj   +1 more source

Immune Checkpoint Inhibitors and Cardiovascular Adverse Events

ESC Heart Failure, EarlyView.
Abstract In the last years, we assisted to a tremendous increase in therapeutic options for the management of cancers, with immunotherapy at the forefront of this innovation. Immune checkpoint inhibitors (ICIs) have been developed to enhance the activity of the immune system against cancer cells (1) and the number of approvals for ICIs has rapidly ...
Maria Luisa De Perna, Elia Rigamonti, Raffaele Zannoni, Vittoria Espeli, Giorgio Moschovitis   +4 more
wiley   +1 more source

"Suboptimal" kidney donors: The experience with tacrolimus-based immunosuppression [PDF]

, 1996
Female, pediatric, and older donors have been associated with inferior graft survival after renal transplantation. We analyzed these three subgroups in 397 patients receiving tacrolimus-based immunosuppression. There were no differences in recipient age,
Alexander, Brenner, Brenner, Darras, Demetris, Gjertson, Gruessner, Hong, Laskow, McCauley, Neugarten, Nghiem, Opelz, Ploeg, Randhawa, Shapiro, Shapiro, Shapiro, Shapiro, Smith, Starzl, Starzl, Thorogood, Vivas   +23 more
core   +1 more source

Drug Interaction Study Of Apixaban With Cyclosporine Or Tacrolimus: Results From A Phase 1, Randomized, Open-Label, Crossover Study In Healthy Volunteers [PDF]

, 2018
BACKGROUND Solid organ transplant recipients commonly require anticoagulation. Apixaban (APX) is principally metabolized by CYP3A4, undergoes direct intestinal excretion, and is a substrate to P-glycoprotein (P-gp) and Breast Cancer Resistance Protein ...
Bashir, MD, Babar, Chervoneva, PhD, Inna, Kraft, MD, Walter K., Mantravadi, MD, Santhi, Stickle, PhD, Douglas F., Tran, PharmD, Benjamin D.   +5 more
core   +1 more source

In vitro Removal of Therapeutic Drugs with a Novel Adsorbent System [PDF]

, 2002
Background/Aim: Substances in the middle molecular weight range have been shown to play a significant pathogenetic role in as diverse disorders as end-stage renal disease and multiple organ failure.
Bellomo, Rinaldo, Bordoni, Valeria, D'Intini, Vincent, Dall'Olio, Giuliano, Galloni, Elisabetta, Reiter, Karl, Ricatti, Maria Grazia, Ronco, Claudio, Ruperti, Salvatore, Soffiati, Giuliano, Soli, Maurizio   +10 more
core   +1 more source

Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matching

Scientific Reports
There is insufficient evidence comparing the outcomes of tacrolimus-based remission induction therapy with infliximab in refractory ulcerative colitis (UC) and evidence regarding optimal strategies after tacrolimus-based remission induction therapy.
Takeo Yoshihara, Takahiro Amano, Shinichiro Shinzaki, Yuri Tsujii, Akiko Asakura, Taku Tashiro, Mizuki Tani, Yuriko Otake-Kasamoto, Takuya Yamada, Yuko Sakakibara, Naoto Osugi, Shuji Ishii, Satoshi Egawa, Manabu Araki, Yuki Arimoto, Masanori Nakahara, Yoko Murayama, Ichizo Kobayashi, Kazuo Kinoshita, Hiroyuki Ogawa, Satoshi Hiyama, Narihiro Shibukawa, Masato Komori, Yorihide Okuda, Takashi Kizu, Tetsuhisa Kitamura, Minoru Kato, Yoshiki Tsujii, Takahiro Inoue, Hideki Iijima, Yoshito Hayashi, Tetsuo Takehara   +31 more
doaj   +1 more source